Acadia Pharma (ACAD): Offering Bridges Commercial Activities To 2019 - Piper Jaffray

August 16, 2016 7:03 AM EDT
Get Alerts ACAD Hot Sheet
Price: $31.22 -0.67%

Rating Summary:
    9 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 29 | Down: 29 | New: 23
Trade ACAD Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Acadia Pharmaceuticals (NASDAQ: ACAD) after ACADIA, yesterday, completed an offering of ~6M shares, raising $188M in net proceeds and pro-forma cash to ~$545M. The analyst believes this offering means the company’s clinical and commercial activities are well-funded into 1H19.

During this time, he expected ACADIA to make significant progress on the NUPLAZID commercial launch in the US and submit a marketing application in the EU. He believes the company can produce positive, potentially pivotal-stage data in AD agitation and advance NUPLAZID in a third possible indication such as schizophrenia or LBD.

Overall, he views the strengthened balance sheet as a positive in terms of supporting the marketing efforts needed for a successful PDP launch and funding clinical development to generate upside additional large-market neuro-psych indications. In advance of increased visibility on early traction in PDP, Phase II ADP data, and a Phase II/III ADA trial start by YE16,

No change to the price target of $44.00

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $32.82 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray, Charles Duncan

Add Your Comment